Notice of Closed Meeting, 12193-12194 [2018-05576]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 54 / Tuesday, March 20, 2018 / Notices
containing a consent order from Nectar
Brand LLC, also d/b/a Nectar Sleep;
Dreamcloud, LLC; and Dreamcloud
Brand LLC (‘‘respondent’’).
The proposed consent order has been
placed on the public record for thirty
(30) days for receipt of comments by
interested persons. Comments received
during this period will become part of
the public record. After thirty (30) days,
the Commission will again review the
agreement and the comments received,
and will decide whether it should
withdraw from the agreement or make
final the agreement’s proposed order.
This matter involves respondent’s
marketing, sale, and distribution of
mattresses with claims that the products
are assembled in the United States.
According to the FTC’s complaint,
respondent represented that its products
are ‘‘assembled in the USA.’’ In fact, the
respondent’s mattresses are wholly
imported. Therefore, this representation
was false or misleading. Based on the
foregoing, the complaint alleges that
respondent engaged in deceptive acts or
practices in violation of Section 5(a) of
the FTC Act.
The proposed consent order contains
provisions designed to prevent
respondent from engaging in similar
acts and practices in the future.
Consistent with the FTC’s Enforcement
Policy Statement on U.S. Origin Claims,
Part I prohibits respondent from making
U.S.-origin claims for their products
unless either: (1) The final assembly or
processing of the product occurs in the
United States, all significant processing
that goes into the product occurs in the
United States, and all or virtually all
ingredients or components of the
product are made and sourced in the
United States; (2) a clear and
conspicuous qualification appears
immediately adjacent to the
representation that accurately conveys
the extent to which the product contains
foreign parts, ingredients or
components, and/or processing; or (3)
for a claim that a product is assembled
in the United States, the product is last
substantially transformed in the United
States, the product’s principal assembly
takes place in the United States, and
United States assembly operations are
substantial.
Part II prohibits respondent from
making any country-of-origin claim
about a product or service unless the
claim is true, not misleading, and
respondent has a reasonable basis
substantiating the representation.
Parts III through V are reporting and
compliance provisions. Part III requires
the filing of compliance reports within
one year after the order becomes final
and within 14 days of any change that
VerDate Sep<11>2014
19:08 Mar 19, 2018
Jkt 244001
would affect compliance with the order.
Part IV requires respondent to maintain
certain records, including records
necessary to demonstrate compliance
with the order. Part V requires
respondent to submit additional
compliance reports when requested by
the Commission and to permit the
Commission or its representatives to
interview respondent’s personnel.
Finally, Part VI is a ‘‘sunset’’
provision, terminating the order after
twenty (20) years, with certain
exceptions.
The purpose of this analysis is to aid
public comment on the proposed order.
It is not intended to constitute an
official interpretation of the proposed
order or to modify its terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018–05613 Filed 3–19–18; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
GH18–004, Advancing Public Health in
Central America (Belize, Costa Rica,
Dominican Republic, El Salvador,
Guatemala, Honduras, Nicaragua,
Panama).
Date: April 17, 2018.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
12193
Officer, Center for Global Health, CDC,
1600 Clifton Drive, Atlanta, GA 30331,
(404) 639–4796; HShoob@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–05577 Filed 3–19–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
GH14–002, Addressing Emerging
Infectious Diseases in Bangladesh;
GH16–003, Conducting Public Health
Research in Thailand: Technical
collaboration with the Ministry of
Public Health in the Kingdom of
Thailand (MOPH); GH16–006,
Conducting Public Health Research in
Kenya; GH17–005, Conducting Public
Health Research in China.
Date: April 10, 2018.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
E:\FR\FM\20MRN1.SGM
20MRN1
12194
Federal Register / Vol. 83, No. 54 / Tuesday, March 20, 2018 / Notices
1600 Clifton Drive, Atlanta, GA 30331,
(404) 639–4796; HShoob@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–05578 Filed 3–19–18; 8:45 am]
[FR Doc. 2018–05576 Filed 3–19–18; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[60Day–18–18JC; Docket No. CDC–2017–
0121]
Centers for Disease Control and
Prevention
Proposed Data Collection Submitted
for Public Comment and
Recommendations
daltland on DSKBBV9HB2PROD with NOTICES
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
GH18–002, Strengthening detection of
emerging infectious diseases in India;
GH18–005, Enhancing Capacity for
Strategic and Applied Research
Activities in Support of Control and
Elimination of Malaria and Neglected
Tropical Diseases.
Date: April 18, 2018.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
1600 Clifton Drive, Atlanta, GA 30331,
(404) 639–4796; HShoob@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
VerDate Sep<11>2014
19:08 Mar 19, 2018
Jkt 244001
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Women’s Health Needs Study:
The Health of U.S.-Resident Women
from Countries with Prevalent Female
Genital Mutilation/Cutting (FGM/C).
DATES: CDC must receive written
comments on or before May 21, 2018.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2017–
0121 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Leroy A.
Richardson, Information Collection
Review Office, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, MS–D74, Atlanta, Georgia
30329; phone: 404–639–7570; Email:
omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Women’s Health Needs Study: The
Health of U.S.-Resident Women from
Countries with Prevalent Female Genital
Mutilation/Cutting (FGM/C)—New—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
E:\FR\FM\20MRN1.SGM
20MRN1
]]>Agencies
[Federal Register Volume 83, Number 54 (Tuesday, March 20, 2018)]
[Notices]
[Pages 12193-12194]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05576]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Management
Analysis and Services Office, CDC, pursuant to Public Law 92-463. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--GH14-002, Addressing Emerging
Infectious Diseases in Bangladesh; GH16-003, Conducting Public Health
Research in Thailand: Technical collaboration with the Ministry of
Public Health in the Kingdom of Thailand (MOPH); GH16-006, Conducting
Public Health Research in Kenya; GH17-005, Conducting Public Health
Research in China.
Date: April 10, 2018.
Time: 9:00 a.m.-2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Hylan Shoob, Ph.D., Scientific
Review Officer, Center for Global Health, CDC,
[[Page 12194]]
1600 Clifton Drive, Atlanta, GA 30331, (404) 639-4796; [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2018-05576 Filed 3-19-18; 8:45 am]
BILLING CODE 4163-18-P
